Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

512 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical Outcomes of Metastatic Renal Carcinoma Following Disease Progression to Programmed Death (PD)-1 or PD-L1 Inhibitors (IO): A Meet-URO Group Real World Study (Meet-Uro 7).
Santini D, Stellato M, De Giorgi U, Pantano F, De Lisi D, Casadei C, Maruzzo M, Bimbatti D, Naglieri E, Buti S, Bersanelli M, De Vivo R, Di Lorenzo G, Sbrana A, Verzoni E, Soraru' M, Fornarini G, Mucciarini C, Grillone F, Mini E, Vignani F, Attademo L, Pignata S, Procopio G. Santini D, et al. Among authors: de lisi d, de vivo r, de giorgi u. Am J Clin Oncol. 2021 Mar 1;44(3):121-125. doi: 10.1097/COC.0000000000000791. Am J Clin Oncol. 2021. PMID: 33617179
Risk of gastrointestinal events with sorafenib, sunitinib and pazopanib in patients with solid tumors: a systematic review and meta-analysis of clinical trials.
Santoni M, Conti A, De Giorgi U, Iacovelli R, Pantano F, Burattini L, Muzzonigro G, Berardi R, Santini D, Cascinu S. Santoni M, et al. Among authors: de giorgi u. Int J Cancer. 2014 Aug 15;135(4):763-73. doi: 10.1002/ijc.28544. Epub 2013 Nov 18. Int J Cancer. 2014. PMID: 24127298 Free article. Review.
Standard vs adapted sunitinib regimen in elderly patients with metastatic renal cell cancer: results from a large retrospective analysis.
De Giorgi U, Scarpi E, Sacco C, Aieta M, Lo Re G, Sava T, Masini C, De Vincenzo F, Baldazzi V, Camerini A, Fornarini G, Burattini L, Rosti G, Ferrari V, Moscetti L, Chiuri VE, Luzi Fedeli S, Amadori D, Basso U. De Giorgi U, et al. Among authors: de vincenzo f. Clin Genitourin Cancer. 2014 Jun;12(3):182-9. doi: 10.1016/j.clgc.2013.11.005. Epub 2013 Nov 15. Clin Genitourin Cancer. 2014. PMID: 24369790
Treatment-related fatigue with sorafenib, sunitinib and pazopanib in patients with advanced solid tumors: an up-to-date review and meta-analysis of clinical trials.
Santoni M, Conti A, Massari F, Arnaldi G, Iacovelli R, Rizzo M, De Giorgi U, Trementino L, Procopio G, Tortora G, Cascinu S. Santoni M, et al. Among authors: de giorgi u. Int J Cancer. 2015 Jan 1;136(1):1-10. doi: 10.1002/ijc.28715. Epub 2014 Feb 7. Int J Cancer. 2015. PMID: 24415642 Free article. Review.
Lymphopenia and clinical outcome of elderly patients treated with sunitinib for metastatic renal cell cancer.
De Giorgi U, Rihawi K, Aieta M, Lo Re G, Sava T, Masini C, Baldazzi V, De Vincenzo F, Camerini A, Fornarini G, Burattini L, Rosti G, Moscetti L, Chiuri VE, Luzi Fedeli S, Ferrari V, Scarpi E, Amadori D, Basso U. De Giorgi U, et al. Among authors: de vincenzo f. J Geriatr Oncol. 2014 Apr;5(2):156-63. doi: 10.1016/j.jgo.2014.01.001. Epub 2014 Jan 22. J Geriatr Oncol. 2014. PMID: 24495699
Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial.
Motzer RJ, Porta C, Vogelzang NJ, Sternberg CN, Szczylik C, Zolnierek J, Kollmannsberger C, Rha SY, Bjarnason GA, Melichar B, De Giorgi U, Grünwald V, Davis ID, Lee JL, Esteban E, Urbanowitz G, Cai C, Squires M, Marker M, Shi MM, Escudier B. Motzer RJ, et al. Among authors: de giorgi u. Lancet Oncol. 2014 Mar;15(3):286-96. doi: 10.1016/S1470-2045(14)70030-0. Epub 2014 Feb 17. Lancet Oncol. 2014. PMID: 24556040 Free PMC article. Clinical Trial.
Sorafenib as first- or second-line therapy in patients with metastatic renal cell carcinoma in a community setting.
Procopio G, Derosa L, Gernone A, Morelli F, Sava T, Zustovich F, De Giorgi U, Ferrari V, Sabbatini R, Gasparro D, Felici A, Burattini L, Calvani N, Lo Re G, Banna G, Pia Brizzi M, Rizzo M, Ciuffreda L, Iacovelli R, Ferraù F, Taibi E, Bracarda S, Porta C, Galligioni E, Contu A. Procopio G, et al. Among authors: de giorgi u. Future Oncol. 2014 Aug;10(10):1741-50. doi: 10.2217/fon.14.48. Epub 2014 Mar 18. Future Oncol. 2014. PMID: 24641206 Free article.
Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study.
Escudier B, Porta C, Bono P, Powles T, Eisen T, Sternberg CN, Gschwend JE, De Giorgi U, Parikh O, Hawkins R, Sevin E, Négrier S, Khan S, Diaz J, Redhu S, Mehmud F, Cella D. Escudier B, et al. Among authors: de giorgi u. J Clin Oncol. 2014 May 10;32(14):1412-8. doi: 10.1200/JCO.2013.50.8267. Epub 2014 Mar 31. J Clin Oncol. 2014. PMID: 24687826 Clinical Trial.
512 results